Stay updated on Daratumumab for AML/High-Risk MDS Clinical Trial
Sign up to get notified when there's something new on the Daratumumab for AML/High-Risk MDS Clinical Trial page.

Latest updates to the Daratumumab for AML/High-Risk MDS Clinical Trial page
- Check6 days agoNo Change Detected
- Check14 days agoChange DetectedAdded Revision: v3.4.2. Removed the notice about lapse in government funding and the previous Revision: v3.4.1 entry.SummaryDifference0.5%

- Check21 days agoChange DetectedAdded a government funding lapse notice and a page revision indicator (v3.4.1). Removed the previous revision indicator (v3.4.0).SummaryDifference0.5%

- Check28 days agoChange DetectedShow glossary was added and labels related to QC updates and No FEAR Act data were adjusted, with the revision tag updated to v3.4.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check42 days agoChange DetectedRevision note updated from v3.3.3 to v3.3.4 on the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check64 days agoChange DetectedLocations section added, listing Texas (MD Anderson Cancer Center) as a site. The Texas Locations heading and the HHS Vulnerability Disclosure link were removed.SummaryDifference0.2%

- Check85 days agoChange DetectedMinor site maintenance update: the page now shows Revision: v3.3.2 (replacing v3.3.1) with no changes to study content or navigation. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Daratumumab for AML/High-Risk MDS Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Daratumumab for AML/High-Risk MDS Clinical Trial page.